4
Changes in Ownership
Ultragenyx Pharmaceutical Inc. Filed Acc 0001209191-22-015833
CFO & Executive Vice President sold 954 shares at an average $65.71 ($62,686)
- CFO & Executive Vice President acquired 14,000 shares (grant or award)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Dier Mardi CFO & Executive Vice President | 2022-03-01 | Sale | −534 | $66.62 | $35,575 | 38,228 | D |
| Dier Mardi CFO & Executive Vice President | 2022-03-01 | Grant or award | +14,000 | 52,228 | D | ||
| Dier Mardi CFO & Executive Vice President | 2022-03-03 | Sale | −420 | $64.55 | $27,111 | 51,808 | D |
| Derivatives | |||||||
| Dier Mardi CFO & Executive Vice President | 2022-03-01 | Grant or award · Stock Option (Right to Buy) | +24,900 | 24,900 | D | ||
| Open-market sales · 954 sh · avg $65.71 · $62,686 | |||||||
Loading xslF345X03/doc4.xml…